Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tincani, E
Right arrow Articles by Bondi, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tincani, E
Right arrow Articles by Bondi, M
Haematologica, Vol 91, Issue 7, 976-979
Copyright © 2006 by Ferrata Storti Foundation

Clinical Trial

Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study

E Tincani, C Mannucci, B Casolari, F Turrini, MA Crowther, D Prisco, AM Cenci, and M Bondi

Unita Operativa Medicina Interna Cardiovascolare, Nuovo Ospedale Civile di Modena S. Agostino-Estense, Baggiovara, Italy. e.tincani@ausl.mo.it

The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to hospital with an acute medical illness. Patients who met the criteria for being at high thromboembolic risk received dalteparin 5,000 IU subcutaneously once daily while the other patients (low risk) received 2,500 IU daily. Thromboprophylaxis was administered for at least 6 days. Anti-Xa activity was determined before the first dalteparin dose and again on day 6, 4 hours after the administration of the dalteparin dose. Bleeding was assessed daily. Compression ultrasonography was performed to identify any deep vein thromboses. There was no evidence of bioaccumulation on day 6 of therapy, irrespective of renal function. No episodes of major bleeding or venous thromboembolism occurred. Larger, randomized studies are warranted to confirm the safety of dalteparin in this patient population.


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
J. Douketis, D. Cook, M. Meade, G. Guyatt, W. Geerts, Y. Skrobik, M. Albert, J. Granton, P. Hebert, G. Pagliarello, et al.
Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin Dalteparin: An Assessment of Safety and Pharmacodynamics: The DIRECT Study
Arch Intern Med, September 8, 2008; 168(16): 1805 - 1812.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. A. Crowther and T. E. Warkentin
Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents
Blood, May 15, 2008; 111(10): 4871 - 4879.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
S. Haas and A. C. Spyropoulos
Primary Prevention of Venous Thromboembolism in Long-Term Care: Identifying and Managing the Risk
Clinical and Applied Thrombosis/Hemostasis, April 1, 2008; 14(2): 149 - 158.
[Abstract] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.